Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Change in Accured Expenses data on file, last reported at -$18.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 30.61% year-over-year to -$18.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $733000.0 (up 133.09% YoY) and the FY2025 annual result came in at -$7.4 million, down 234.21% from the prior year.
• Change in Accured Expenses retreated to -$18.5 million in Q1 2026, from $15.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.8 million in Q4 2025 to a low of -$26.6 million in Q1 2025.
• A 5-year average of -$835058.8 and a median of $2.8 million in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 641.26% in 2022, down 11680.0% in 2022.
• Tracing RXRX's Change in Accured Expenses over 5 years: stood at $12.2 million in 2022, then plunged by 77.12% to $2.8 million in 2023, then surged by 278.01% to $10.5 million in 2024, then jumped by 50.56% to $15.8 million in 2025, then slumped by 216.49% to -$18.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$18.5 million (Q1 2026), $15.8 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.